Maintenance therapy of celecoxib for major depression with mimicking neuropsychological dysfunction

General Hospital Psychiatry

Volumn 32, Issue 6, 2010, Pages 647.e7-647.e9

  Chen, Chun Yen ^a   Tzeng, Nian Sheng ^a   Chen, Yi Chyan ^a,b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Celecoxib; Inflammation; Major depression; Remission

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CELECOXIB; METFORMIN; MIDAZOLAM; SERTRALINE; TRAZODONE;

ABSENCE OF SIDE EFFECTS; ACUTE DISEASE; AGED; ARTICLE; CASE REPORT; COGNITIVE DEFECT; DIABETES MELLITUS; DIZZINESS; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; INSOMNIA; MAINTENANCE THERAPY; MAJOR DEPRESSION; PAIN; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PSEUDODEMENTIA; PSYCHOMOTOR RETARDATION; PSYCHOPATHY; RELAPSE; REMISSION; SUICIDE ATTEMPT; THOUGHT DISORDER; TREATMENT DURATION;

EID: 78649505983     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2010.07.001     Document Type: Article

References (15)

1. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009, 65:732-741.
2. Muller N., Schwarz M.J. COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des 2008, 14:1452-1465.
3. Akhondzadeh S., Jafari S., Raisi F., et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009, 26:607-611.
4. Goldstein B.I., Kemp D.E., Soczynska J.K., McIntyre R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009.
5. Danese A., Moffitt T.E., Pariante C.M., et al. Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry 2008, 65:409-415.
6. 2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment. J Neurosci 2009, 29:14-22.
7. Muller N., Schwarz M.J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 2007, 12:988-1000.
8. Muller N., Schwarz M.J., Dehning S., et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006, 11:680-684.
9. Hu F., Wang X., Pace T.W., Wu H., Miller A.H. Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function. Mol Psychiatry 2005, 10:426-428.
10. Guo J.Y., Li C.Y., Ruan Y.P., et al. Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. Eur J Pharmacol 2009, 612:54-60.
11. Muller N., Riedel M., Schwarz M.J., Engel R.R. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2005, 255:149-151.
12. Qin W., Peng Y., Ksiezak-Reding H., et al. Inhibition of cyclooxygenase as potential novel therapeutic strategy in N141I presenilin-2 familial Alzheimer's disease. Mol Psychiatry 2006, 11:172-181.
13. Scali C., Giovannini M.G., Prosperi C., et al. The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo. Neuroscience 2003, 117:909-919.
14. Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?. Lancet 2007, 370:2138-2151.
15. Huang W.F., Hsiao F.Y., Tsai Y.W., Wen Y.W., Shih Y.T. Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. Drug Saf 2006, 29:261-272.